Biodegradable microparticles that help the immune system tolerate autoimmune diseases

Biodegradable polymeric microparticles comprised of acetalated dextran induce immune tolerance

['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11027894

This study is exploring a new treatment made from biodegradable particles that can help people with autoimmune diseases, like multiple sclerosis, by encouraging the body to calm down its immune response and reduce symptoms.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIV OF NORTH CAROLINA CHAPEL HILL (nih funded)
Locations1 site (CHAPEL HILL, UNITED STATES)
Trial IDNIH-11027894 on ClinicalTrials.gov

What this research studies

This research investigates the use of biodegradable microparticles made from acetalated dextran to promote immune tolerance in patients with autoimmune diseases. The microparticles are designed to specifically bind to B cells, triggering the production of a cytokine called IL-10, which helps to reduce the immune response against the body's own tissues. By using a unique spray drying technique, these microparticles have shown promising results in animal models, particularly in reducing symptoms of multiple sclerosis. The goal is to develop a targeted therapy that avoids the broad immunosuppression typically used in treating autoimmune conditions.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases, particularly those experiencing symptoms related to conditions like multiple sclerosis.

Not a fit: Patients with non-autoimmune conditions or those who do not have a response to B cell-targeted therapies may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to a new treatment option that specifically targets autoimmune diseases without the side effects of general immunosuppression.

How similar studies have performed: While the approach of using biodegradable microparticles for immune tolerance is innovative, similar strategies have shown promise in preclinical models, indicating potential for success.

Where this research is happening

CHAPEL HILL, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.